PRAX: Other company developments

Item 8.01. Other Events. On July 7, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced that the Company entered into a research collaboration and license agreement (the “Agreement”) with Remagine Labs, Inc., a developer of electronically controlled transdermal drug delivery systems (“Remagine”), to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide for essential tremor. Under the Agreement, the Company and Remagine will collaborate to apply Remagine’s proprietary platform, designed for precise, multi-day active transdermal dosing, to ulixacaltamide, complementing the Company’s lead oral program. A transdermal option is intended to broaden the population ulixacaltamide can reach, while strengthening ulixacaltamide’s competitive positioning and extending the long-term value of the franchise. The Company has also made an equity investment in Remagine, underscoring the companies’ shared commitment to quickly advancing the program. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the Company’s strategic collaboration with Remagine and the development and potential market opportunity of ulixacaltamide. The forward-looking statements included in this Current Report on Form 8-K are subject to a number of risks, including, without limitation, uncertainties inherent in clinical trials and other risks as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and other filings with the Securities and Exchange Commission. These statements are based only on facts currently known by the Company and speak only as of the date o